Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2025 10:24 ET | Source: Actuate Therapeutics

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

- Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma...
April 17, 2025 08:00 ET | Source: Actuate Therapeutics

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

CHICAGO and FORT WORTH, Texas, April 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on...
February 25, 2025 08:00 ET | Source: Actuate Therapeutics

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

Initial Data from this Phase 2 Trial Demonstrates Early Evidence of Clinical Activity of Elraglusib (9-ING-41) in Combination with FOLFIRINOX and Losartan in Untreated Metastatic Pancreatic Ductal...
February 06, 2025 08:00 ET | Source: Actuate Therapeutics

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

CHICAGO and FORT WORTH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on...
January 07, 2025 08:00 ET | Source: Actuate Therapeutics

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

CHICAGO and FORT WORTH, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on...
December 17, 2024 08:28 ET | Source: Actuate Therapeutics

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate and 37% Reduction in Risk of Death Two Month (29%) Increase in...
December 17, 2024 08:00 ET | Source: Actuate Therapeutics

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate and 37% Reduction in Risk of Death Two Month (29%) Increase in...
November 26, 2024 08:00 ET | Source: Actuate Therapeutics

Actuate Therapeutics to be Added to Russell 2000® Index

CHICAGO and FORT WORTH, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on...
November 12, 2024 08:00 ET | Source: Actuate Therapeutics

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumor in Children and AdolescentsOngoing Enrollment in Phase 1/2 Trial of Elraglusib in...
October 29, 2024 18:39 ET | Source: Actuate Therapeutics

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate’s lead investigational drug product, elraglusib ...